Table 1.

Baseline demographic and disease characteristics

	n	Age (y)	Sex (M/F)	Disease duration (y)	CDAI	CRP (mg/dl)	sICAM* (ng/ml) (median (range))	Steroid dose (mg/day) (median (range) [% in high dose stratum])
ISIS 2302
2 Week	99	39.2 (12.9)	36/63	11.0 (10.7) [0.1–78.7]	283.7 (51.6)	4.33 (15.0)	253 (63–630)	70 (10–40) [62]
4 Week	99	39.3 (11.9)	36/63	9.1 (7.4) [0.2–38.5]	274.4 (52.8)	3.55 (10.1)	215 (82–881)	20 (10–45) [61]
All ISIS 2302	198	39.3 (12.9)	72/126	10.1 (9.3) [0.1–78.7]	279.1 (52.3)	3.95 (12.8)	230 (63–881)	20 (10–45) [61]
Placebo	101	39.2 (12.1)	40/61	9.8 (8.3) [1.0–50.4]	269.3 (54.2)	2.46 (6.3)	234 (71–784)	20 (10–55) [64]

Unless otherwise stated, values are mean (SD) [range].

*257 subjects serotyped for serological patterns and 171 tested for baseline sICAM values.

CDAI, Crohn's disease activity index; sICAM, soluble intercellular adhesion molecule; CRP, C reactive protein.